Pavilion Compounding Pharmacy, Atlanta, GA
Is Pavilion Compounding Pharmacy registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Pavilion Compounding Pharmacy hold a Georgia pharmacy license?
State board of pharmacy records for Georgia are not checked: no license file or list of board orders was found on the board’s website when checked on November 10, 2026; its license verification is an interactive search.
Has Pavilion Compounding Pharmacy had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Nov 6, 2020), 1 state referral letter (May 20, 2021) and 1 FMD-145 letter (May 20, 2021) for Pavilion Compounding Pharmacy. State board of pharmacy records for Georgia are not checked: no license file or list of board orders was found on the board’s website when checked on November 10, 2026; its license verification is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Pavilion Compounding Pharmacy
- Location
- Atlanta, GA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- May 20, 2021
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 5 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Pavilion Compounding Pharmacy, a 503A facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| May 20, 2021 | State referral letter | State Referral Letter Issued 05/20/2021 | Not linked by FDA |
| May 20, 2021 | FMD-145 letter | FMD-145 Letter Issued 05/20/2021 | Not linked by FDA |
| Nov 6, 2020 | Untitled letter | Untitled Letter Issued 11/06/2020 | FDA copy (archived) |
| Feb 27, 2019 | Response to Form 483 | 483 Response Dated 02/27/2019 | fda.gov |
| Feb 8, 2019 | Form 483 | 483 Issued 02/08/2019 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Pavilion Compounding Pharmacy, Atlanta, GA (FEI number 3004570352), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Feb 8, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3004570352 | 1078659 |
Form 483s FDA has published for this site
- Feb 8, 2019: Form 483 to Pavilion Compounding Pharmacy, published Aug 9, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 5 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Feb 4, 2019 to Feb 8, 2019: 5 observations
- Firm on the cover
- Pavilion Compounding Pharmacy, 3200 Downwood Cir Nw Ste 210, Atlanta, GA 30327-1611
- FEI number
- 3004570352
- Establishment type on the cover
- Producer of sterile and non-sterile drugs
- FDA district office on the cover
- 60 Eighth Street NE Atlanta, GA 30309
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You produced hazardous drugs without providing adequate containment, segregation and cleaning of personnel to prevent cross-contamination.
Specifically, hormone and non-hormone containing drugs are prepared in your negative pressure, non-sterile room without any gowning controls or cleaning procedures in place to prevent cross-contamination between batches. On 02/04/2019, I observed the production of Testosterone LD Topical 8mg/mL Cream (lot 02042019@22) and BIEST (80:20)/Prog LD Topical 3/30mg/GM Cream (lot 02042019@23) in the same area as non-hazardous Bleach-Ease (Nourivan) 8% Cream (lot 02042019@1).
Observation 2
Unsealed, loose ceiling tiles were observed in your cleamnroom.
Specifically, a gap was observed in the ceiling of the ISO 7 ante room around the HEPA filter.
Observation 3
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
Specifically, your fnm does not perform potency testing prior to release for non-sterile drug formulations. Examples include, but are not limited to the following non-sterile drug products:
Canthardin Plus Topical I% Liquid, Lot 01032019@75
Phenylephline HCL/Lidocaine HCL Nasal 1 %/4% Solution, Lot 11282018@32
PhenylephI·ine 1 % Solution, Lot 05092018@45
Observation 4
Batch production and control records do not include complete information relating to the production and control of each batch.
Specifically, your firm' s formul a worksheets do not include the following information for non-sterile drug products:
Identity of major equipment used
Laboratory results
Inspection of packaging and labeling
A statement of actual yield
Specimens of labeling
Example include, but are not limited to the following:
Canthardin Plus Topical 1% Liquid, Lot 01032019@75
Phenylephline HCL/Lidocaine HCL Nasal 1%/4% Solution, Lot 11282018@32
PhenylephI·ine 1 % Solution, Lot 05092018@45
Observation 5
Procedures designed to prevent insanitaiy conditions are not established or followed.
Specifically,
A) Media fills are not representative of all routine aseptic operations. For example, media fills are not performed for vial filling operations. For example, your firm produced Glutathione Solution 200mg/mL Injectable, Lot 01292019@18 which was produced in a vial.
B) There is no documentation or evidence to show that smoke studies are performed under dynamic conditions in your hazardous and non-hazardous ISO 5 glove boxes.
C) Your firm does not perform endotoxin testing for each lot of intrathecal drug product prepared. For example, your firm produced Morphine Sulfate (PF) 20mg/mL Injectable, Lot 01312019@1 for intrathecal use however there was no endotoxin testing performed prior to release for use.
D) Your firm has no evidence that filter integrity testing on filters were performed when dispensing finished drug products from stock solutions. For example, your firm produced Vitainin B Complex 100 Injectable, Lot 10292018@10, BUD 12/13/18 in a bulk syringe which was then frozen. ...
State board of pharmacy records
State board of pharmacy records for Georgia are not checked: no license file or list of board orders was found on the board’s website when checked on November 10, 2026; its license verification is an interactive search.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.